Log in

Relevant bibliographies by topics / Chemotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Chemotherapy.

Journal articles on the topic 'Chemotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Akl, Maher Monir. "Glucosodiene: Opening a New Branch of Chemotherapic Sciences Called Toxinutromedicanical-Chemotherapy." Cell & Cellular Life Sciences Journal 8, no. 2 (2023): 1–2. http://dx.doi.org/10.23880/cclsj-16000185.

Full text

Abstract:

Chemotherapy is a widely employed treatment modality in the fight against cancer aiming to eliminate both normal and cancerous cells. However, its non-discriminatory nature leads to severe side effects

APA, Harvard, Vancouver, ISO, and other styles

2

Armini, Ni ketut alit, Masfin Muhayanah, and Aria Nastiti. "DIARRHEA INCIDENT IN CERVICAL CANCER PATIENTS POST CHEMOTHERAPY TREATMENT." Jurnal NERS 11, no. 1 (April 1, 2016): 106. http://dx.doi.org/10.20473/jn.v11i12016.106-111.

Full text

Abstract:

Backgrounds : Cervical cancer is second most diseases suffered by women. Chemotherapy is primary treatment for cervical cancer. Chemotherpy has some side effect, and one of them is diarrhea. Diarrhea make cervical cancer suffered more. The purpose of this research was to analyze the correlation of factor’s that cause diarrhea on cervical cancer.Methods : This research uses descriptive analitic method with retrospective design. The population in this research is all patients who had post first chemotherapy. Sample in this study were 21 respondents, with purposive sampling. Variable independent were type of chemotherapy drugs, character of chemotheraphy, staging, stress and dietary. Variable dependent was diarrhea. Data collected using quesionare. Data were analyzed using chi square test with level of significant α≤0,05.Results : The result of the study reveals that type of the chemotherapy drug p:0,598, character of chemotheraphy p:0,336,. Staging has correlation with diarrhea significant of p:0,022. Stress and dietary analysisis presented p:0,00. It means that there was significant correlation with diarrhea.Conclusion : It can be concluded that diarrhea incident related to staging, stress and dietarry. There‘s no correlation between type of chemotherapy drug, character of chemotheraphy with diarrhea Further studies should give health education about dietary causing diarrhea, chemotherapy procedural and sides effect’s, increase supports for patient with cervical cancer. Keyword: Cervical Cancer, Chemotherapy, Diarrhea.

APA, Harvard, Vancouver, ISO, and other styles

3

Armini, Ni ketut alit, Masfin Muhayanah, and Aria Nastiti. "The Incident of Diarrhea among Cervical Cancer Patients Post Chemoterapy Treatment." Jurnal Ners 11, no. 1 (April 1, 2016): 106–11. http://dx.doi.org/10.20473/jn.v11i1.1357.

Full text

Abstract:

Backgrounds : Cervical cancer is second most diseases suffered by women. Chemotherapy is primary treatment for cervical cancer. Chemotherpy has some side effect, and one of them is diarrhea. Diarrhea make cervical cancer suffered more. The purpose of this research was to analyze the correlation of factor’s that cause diarrhea on cervical cancer.Methods : This research uses descriptive analitic method with retrospective design. The population in this research is all patients who had post first chemotherapy. Sample in this study were 21 respondents, with purposive sampling. Variable independent were type of chemotherapy drugs, character of chemotheraphy, staging, stress and dietary. Variable dependent was diarrhea. Data collected using quesionare. Data were analyzed using chi square test with level of significant α≤0,05.Results : The result of the study reveals that type of the chemotherapy drug p:0,598, character of chemotheraphy p:0,336,. Staging has correlation with diarrhea significant of p:0,022. Stress and dietary analysisis presented p:0,00. It means that there was significant correlation with diarrhea.Conclusion : It can be concluded that diarrhea incident related to staging, stress and dietarry. There‘s no correlation between type of chemotherapy drug, character of chemotheraphy with diarrhea Further studies should give health education about dietary causing diarrhea, chemotherapy procedural and sides effect’s, increase supports for patient with cervical cancer.

APA, Harvard, Vancouver, ISO, and other styles

4

Dougherty, Lisa. "Practical Chemotherapy Practical Chemotherapy." Nursing Standard 17, no. 41 (June 25, 2003): 29. http://dx.doi.org/10.7748/ns2003.06.17.41.29.b333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

S., Karthik, Seenivasan P., and Rajanandh M.G. "Pattern of Chemotherapy Induced Alopecia." Indian Journal of Cancer Education and Research 4, no. 2 (2016): 45–47. http://dx.doi.org/10.21088/ijcer.2321.9815.4216.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Fitrianingsih, Nining. "HUBUNGAN TINGKAT PENGETAHUAN PERAWAT TENTANG KEMOTERAPI DENGAN TINDAKAN PEMBERIAN KEMOTERAPI PADA PASIEN KANKER PARU." Jurnal Persatuan Perawat Nasional Indonesia (JPPNI) 1, no. 3 (March 16, 2017): 207. http://dx.doi.org/10.32419/jppni.v1i3.31.

Full text

Abstract:

ABSTRAKLatar Belakang: Kemoterapi merupakan salah satu cara pengobatan kanker dengan memberikanobat atau zat yang berkhasiat membunuh sel kanker. Dalam tindakan medis, perawat harusmemiliki pengetahuan tentang prosedur pemberian obat kemoterapi karena pemberian kemoterapiyang dilakukan oleh perawat rentan terkena pada kulit atau mata pada saat melakukan tindakan.Tujuan Penelitian: mengetahui hubungan tingkat pengetahuan perawat tentang kemoterapidengan tindakan pemberian kemoterapi pada pasien kanker paru. Metode: Desain penelitianyang digunakan ialah analisis korelasional dengan pendekatan cross sectional. Populasi yangditeliti adalah perawat berjumlah 46 dengan teknik pengambilan sampel total sampling. Instrumenpenelitian berupa uesioner dan lembar observasi. Analisis data secara univariat dan divariat. Hasil:hasil penelitian menunjukkan nilai uji statistik chi square dengan p value = 0,001 (≤ 0,05), hal iniberarti ada hubungan antara tingkat pengetahuan perawat tentang kemoterapi dengan tindakanpemberian kemoterapi pada pasien kanker paru. Diskusi: seseorang yang mempunyai tingkatpengetahuan, pengalaman kerja yang banyak, serta diikuti bertambahnya usia akan memberikanpelayanan/perawatan dalam pemberian kemoterapi yang lebih baik hasilnya. Simpulan: perawatyang memiliki pengetahuan yang baik tentang kemoterapi akan memberikan tindakan kemoterapiyang sesuai dengan prosedur.Kata Kunci: Pengetahuan, kemoterapi, kanker paru.THE CORRELATION BETWEEN KNOWLEDGE LEVEL OF NURSES ABOUT CHEMOTHERAPHYAND CHEMOTHERAPHY ADMINISTRATION IN LUNG CANCER PATIENTSABSTRACTBackground: Chemotherapy is one of the methods in treating cancer by providing effi cacious drugs orsubstances that kill cancer cells. In a medical procedure, nurses must have knowledge of proceduresfor chemotherapy regimens because the chemotherapy conducted by nurses is susceptible to skinor eyes at the time of the intervention. Objective: To identify the correlation between knowledgelevel of nurses about chemotheraphy and chemotheraphy administration in lung cancer patients.Methods: This study was correlational analytical with cross sectional approach. Samples were46 nurses taken using total sampling technique. Questionnaire observation sheet were used asinstruments. Data was analyzed with univariate and bivariate. Results: There was a correlationbetween knowledge level of nurses about chemotherapy and chemotherapy administration, pvalue=0.001 (≤ 0.05). Discussion: One who has higher level of knowledge, a lot of work experience,and get older will administer better chemotherapy. Conclusions: Nurses with comprehensiveknowledge of chemotherapy will administer chemotherapy in accordance with procedure.Keywords: Knowledge level, Chemotherapy, Lung Cancer

APA, Harvard, Vancouver, ISO, and other styles

7

Winata, I. Gde Sastra GdeSastra. "Neoadjuvant Chemotherapy In Stadium Ib3, Iia2 And Iib Cervical Cancer." Andalas Obstetrics And Gynecology Journal 7, no. 1 (March 2, 2023): 214–24. http://dx.doi.org/10.25077/aoj.7.1.214-224.2023.

Full text

Abstract:

Aim:Â This studyÂ aimed to describe Paclitaxel-Carboplatin chemotherapy as neoadjuvant chemotherapy in stage IB3, IIA2 and IIB cervical cancer.Â Materials and Methods:Â The review was conducted by collecting journals from previous studies discussing neoadjuvant chemotherapy in cervical cancer stages IB3, IIA2, and IIB and in this case specifically discussing Paclitaxel-Carboplatin chemotherapy.Â Results:Â Neoadjuvan chemotherapy refers to systemic therapy intended to reduce the size of the tumor before the definitive operation. Several studies have shown that neoadjuvant chemotherapy has greater advantages than surgery alone for early stage cancers (IB3, IIA2, and IIB). Paclitaxel and Carboplatin are known chemotherapeutic agents that can be used as neoadjuvant chemotherapy.Â Conclusions:Â Neoadjuvant Chemotherapy regimen Paclitaxel Carboplatin is one of the options in performing therapy for early stage cervical cancer which can be very helpful in healing and cancer-free patient condition. Neoadjuvant chemotherapy followed by radical surgery has significant benefits that have been described in several previous studies.Â Â Clinical Significance:Â Neoadjuvant Chemotherapy regimen Paclitaxel Carboplatin may be used as therapy regimen for early stage cervical cancer with all advantage compared to only surgery. Thus, this type of regimen can be used to decrease mortality and morbidity in patient with stadium IB3, IIA2 and IIB cervical cancer.Â

APA, Harvard, Vancouver, ISO, and other styles

8

Friedrich, Michael, Alexander Khudyakov, Arne Terjung, Wolfgang Zinn, and Ulrich Füllers. "Influence of hyperthermic intraperitoneal chemotherapy (HIPEC) on the onset of adjuvant chemotherapy in ovarian cancer." Voprosy ginekologii, akušerstva i perinatologii 21, no. 2 (2022): 14–17. http://dx.doi.org/10.20953/1726-1678-2022-2-14-17.

Full text

Abstract:

Objective. To determine the benefits of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced ovarian cancer. Patients and methods. The study included 87 patients, while 74 patients had epithelial ovarian cancer and 13 patients showed other neoplasms. At the end of the operation, a 1-hour perfusion of the abdominal cavity was performed with cisplatin 50 mg/m2 at a temperature of 41°C. The patient data was retrospectively analyzed considering the time interval of postoperative chemotherapy based on the guideline. Results. Sixty patients manifested macroscopic tumor clearance (81.1%), 13 patients (17.6%) – residual tumor <1 cm, and 1 patient (1.4%) – a residual tumor >1 cm. Postoperative chemotherapy was performed in 72 patients (92.3%). The average interval between HIPEC and induction of postoperative chemotherapy lasted 37 days. Conclusion. In case of complete resection of the tumor, intraperitoneal chemotherapy with cisplatin can improve the prognosis for advanced ovarian cancer. HIPEC does not reduce the use of postoperative systemic chemotherapy, though a new approach to chemotherapy presented in the article facilitates a more uniform distribution of the chemotherapeutic drug inside the intraperitoneal cavity, and, thereby, micro metastases in the late stages of ovarian cancer are more effectively suppressed. Key words: epithelial ovarian cancer, intraoperative hyperthermic intraperitoneal chemotherapy, cisplatin, postoperative chemotherapy

APA, Harvard, Vancouver, ISO, and other styles

9

Chung, Fu-Tsai, Ming-Yun Ho, Yueh-Fu Fang, Meng-Heng Hshieh, Tsai-Yu Wang, Chih-Hsi Kuo, Hao-Cheng Chen, et al. "The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on DifferentEGFRMutation Lung Adenocarcinoma." BioMed Research International 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/948267.

Full text

Abstract:

Objectives. Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial.Methods. Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy:n= 56 and 2nd-line chemotherapy:n= 55). Their outcomes profiles were analyzed.Results. The overall survival (OS) of all patients (390 versus 662 days,p< 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days,p= 0.0001) and OS (308 versus 704 days,p= 0.0001) of patients withL858Rmutation (n= 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, andL858Rmutation were significantly related to poor PFS and OS.Conclusion. In advanced lung adenocarcinoma,L858Rmutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.

APA, Harvard, Vancouver, ISO, and other styles

10

(R.T), Dr C. S. K. Prakash, M. D. "Nasopharyngeal Carcinoma- Role of External Beam Radiotherapy (EBRT) and Chemotherapy Vs EBRT, Chemotherapy and Intraluminal Brachytherapy." Journal of Medical Science And clinical Research 04, no. 10 (October 27, 2016): 13348–61. http://dx.doi.org/10.18535/jmscr/v4i10.92.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Takahashi, M. "Chemotherapy." Nihon Kikan Shokudoka Gakkai Kaiho 72, no. 2 (April 10, 2021): 93–96. http://dx.doi.org/10.2468/jbes.72.93.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Deasy, Michael J. "Chemotherapy." Dental Clinics of North America 34, no. 1 (January 1990): 1–11. http://dx.doi.org/10.1016/s0011-8532(22)01158-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Engelking, Constance. "Chemotherapy." American Journal of Nursing 87, no. 11 (November 1987): 1438. http://dx.doi.org/10.2307/3425898.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Pope, Robert. "Chemotherapy." Academic Medicine 92, no. 1 (January 2017): 76. http://dx.doi.org/10.1097/acm.0000000000001492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Smith, Dorothy B. "Chemotherapy." Journal of Wound, Ostomy and Continence Nursing 15, no. 3 (May 1988): 138–39. http://dx.doi.org/10.1097/00152192-198805000-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Gordon, Philip H. "Chemotherapy." Diseases of the Colon & Rectum 61, no. 3 (March 2018): 275–78. http://dx.doi.org/10.1097/dcr.0000000000001040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Grajny, Agatha E., Donna Christie, Anna M. Tichy, and Marie L. Talashek. "Chemotherapy." Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional 11, no. 5 (September 1993): 51–58. http://dx.doi.org/10.1097/00004045-199309000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

OMURA, G. A. "Chemotherapy." JNCI Journal of the National Cancer Institute 84, no. 19 (October 7, 1992): 1532–33. http://dx.doi.org/10.1093/jnci/84.19.1532-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Kozlowski, James M. "Chemotherapy." Journal of Urology 147, no. 3 Part 2 (March 1992): 938–41. http://dx.doi.org/10.1016/s0022-5347(17)37428-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Terry, Anna R., and Scott R. Plotkin. "Chemotherapy:." Otolaryngologic Clinics of North America 45, no. 2 (April 2012): 471–86. http://dx.doi.org/10.1016/j.otc.2011.12.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Pinedo, Herbert M., and Giuseppe Giaccone. "Chemotherapy." Lancet 349 (May 1997): S7—S9. http://dx.doi.org/10.1016/s0140-6736(97)90012-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Canter, Robert J. "Chemotherapy." Surgical Oncology Clinics of North America 25, no. 4 (October 2016): 861–72. http://dx.doi.org/10.1016/j.soc.2016.05.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Needleman, Richard. "Chemotherapy." AAOHN Journal 35, no. 4 (April 1987): 179–82. http://dx.doi.org/10.1177/216507998703500408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Lewis, Brian J. "Chemotherapy." International Journal of Radiation Oncology*Biology*Physics 17 (January 1989): 106. http://dx.doi.org/10.1016/0360-3016(89)90618-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Arnold, R., A. Rinke, Ch Schmidt, and L. Hofbauer. "Chemotherapy." Best Practice & Research Clinical Gastroenterology 19, no. 4 (August 2005): 649–56. http://dx.doi.org/10.1016/j.bpg.2005.04.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sugerman, Deborah Tolmach. "Chemotherapy." JAMA 310, no. 2 (July 10, 2013): 218. http://dx.doi.org/10.1001/jama.2013.5525.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Grunberger, Aimée. "Chemotherapy." JAMA: The Journal of the American Medical Association 273, no. 7 (February 15, 1995): 534b. http://dx.doi.org/10.1001/jama.1995.03520310030024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Rousseau, Paul. "Chemotherapy." JAMA 298, no. 6 (August 8, 2007): 604. http://dx.doi.org/10.1001/jama.298.6.604.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Li, Yiu-Tai, Szu-Ting Yang, and Peng-Hui Wang. "Chemotherapy adjuvant and chemotherapy-induced neutropenia." Taiwanese Journal of Obstetrics and Gynecology 61, no. 4 (July 2022): 573–74. http://dx.doi.org/10.1016/j.tjog.2022.05.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Ernani, Vinicius. "Nasopharyngeal Carcinoma: Chemotherapy or No Chemotherapy?" Journal of Oncology Practice 14, no. 10 (October 2018): 607–8. http://dx.doi.org/10.1200/jop.18.00532.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Henderson, Craig. "Chemotherapy treatments: chemotherapy for breast cancer." International Journal of Radiation Oncology*Biology*Physics 24 (January 1992): 93–94. http://dx.doi.org/10.1016/0360-3016(92)90075-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Moha, Rico. "Chemotherapy medication of Vincristine and Vinblastine." Cancer Research and Cellular Therapeutics 1, no. 1 (December 8, 2017): 01–02. http://dx.doi.org/10.31579/2640-1053/007.

Full text

Abstract:

Cancers treated with Vincristine and vinblastine include: acute leukemia, Hodgkin's and non- Hodgkin's lymphoma, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, Wilms' tumor, multiple myeloma, chronic leukemias, thyroid cancer, brain tumors, non-small cell lung cancer, bladder cancer, melanoma, and testicular cancer andIt is also used to treat some blood disorders. It is given by injection into a vein. Vincristine and vinblastine exhibit differential activity against tumors and normal tissues. In this work, a number of cultured cell lines were assayed for their sensitivity to the antiproliferative and cytotoxic effects of the two drugs following short-term (4 hr) or during continuous exposures. Differential activity was not seen when cells were subjected to continuous exposures. The concentrations of Vincristine and vinblastine, respectively, that inhibited growth rates by 50% were: mouse leukemia L1210 cells, 4.4 and 4.0 nw; mouse lymphoma S49 cells, 5 and 3.5 nM; mouse neuroblastoma cells, 33 and 15 nw; HeLa cells, 1.4 and 2.6 nw; and human leukemia HL-60 cells, 4.1 and 5.3 nM. In contrast, differential toxicity was seen when cells were subjected to 4-hr exposures and transferred to drug-free medium: the 50% growth-inhibitory concentrations for Vincristine and vinblastine, respectively, for inhibition (a) of proliferation of L1210 cells were 100 and 380 nM and of HL-60 cells were 23 and 900 nM and (b) of colony formation of L1210 cells were 6 and >600 nM and of HeLa cells were 33 and 62 nM. Uptake and release of [3H]- vincristine and [3H]vinblastine were examined in L1210 cells under the conditions of growth experiments. Uptake of both drugs was dependent on the pH of culture media, and signifi cantly greater amounts of [3H]vinblastine than of [3H]vincristine were associated with cells after 4-hr exposures to equal concen trations of either drug. When cells were transferred to drug-free medium after 4-hr exposures, vinblastine was released much more rapidly from cells than was Vincristine, and by 0.5 hr after resuspension of cells, the amount of Vincristine associated with the cells was greater than the amount of vinblastine and remained so for up to at least 6 hr.

APA, Harvard, Vancouver, ISO, and other styles

33

Yamashita, Tatsuya. "Chemotherapy for advanced hepatocellular carcinoma: systemic chemotherapy or hepatic arterial infusion chemotherapy?" Journal of Gastroenterology 39, no. 4 (April 1, 2004): 404–6. http://dx.doi.org/10.1007/s00535-004-1330-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Middleton, Justin, Daniel Stover, and Tsonwin Hai. "Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response." International Journal of Molecular Sciences 19, no. 11 (October 26, 2018): 3333. http://dx.doi.org/10.3390/ijms19113333.

Full text

Abstract:

An emerging picture in cancer biology is that, paradoxically, chemotherapy can actively induce changes that favor cancer progression. These pro-cancer changes can be either inside (intrinsic) or outside (extrinsic) the cancer cells. In this review, we will discuss the extrinsic pro-cancer effect of chemotherapy; that is, the effect of chemotherapy on the non-cancer host cells to promote cancer progression. We will focus on metastasis, and will first discuss recent data from mouse models of breast cancer. Despite reducing the size of primary tumors, chemotherapy changes the tumor microenvironment, resulting in an increased escape of cancer cells into the blood stream. Furthermore, chemotherapry changes the tissue microenvironment at the distant sites, making it more hospitable to cancer cells upon their arrival. We will then discuss the idea and evidence that these devastating pro-metastatic effects of chemotherapy can be explained in the context of adaptive-response. At the end, we will discuss the potential relevance of these mouse data to human breast cancer and their implication on chemotherapy in the clinic.

APA, Harvard, Vancouver, ISO, and other styles

35

Ardhiansyah, Azril Okta, IB Tjakra Wibawa Manuaba, and I. Ketut Widiana. "Post-Chemotherapy Monocytopenia as a Predictor of Chemotherapy – Induced Neutropenia in Breast Cancer Patients." Bali Medical Journal 11, no. 3 (September 28, 2022): 1325–30. http://dx.doi.org/10.15562/bmj.v11i3.2844.

Full text

Abstract:

Background: Chemotherapy-induced neutropenia (CIN) is chemotherapy's most frequent myelosuppression effect. Previous studies have examined static prognostic factors to assess dynamic neutrophil changes in each cycle. This study focuses on post-chemotherapy monocytopenia as a more dynamic predictor of CIN. This research aimed to know whether post-chemotherapy monocytopenia can be used as a predictor of CIN in breast cancer patients undergoing the chemotherapy cycle. Methods: This research used a prospective and a retrospective longitudinal cohort of breast cancer patients undergo a CAF regimen at Sanglah Hospital Denpasar. The research was conducted on 30 samples for three cycles (90 total cycles). Monocyte data is taken in the first week (days 4 to 9), and neutrophil data is taken in the second week (days 10 to 16). Results: From statistical analysis with interval data scale, we obtained that p 0.001 with Pearson correlation 0.613 for cycle 1, p 0.001 with Pearson correlation 0.611 for cycle 2, and p 0.003 with Pearson correlation 0.522 for cycle 3. Conclusions: In conclusion, post-chemotherapy monocytopenia can be used to predict the occurrence of chemotherapy-induced neutropenia (CIN) with the strongest positive correlation in the first cycle.

APA, Harvard, Vancouver, ISO, and other styles

36

Raval, Vishal, R. Christopher Bowen, Hansell Soto, and Arun Singh. "Chemotherapy for Retinoblastoma: Impact of Intravitreal Chemotherapy." Asia-Pacific Journal of Ophthalmology 10, no. 2 (September 9, 2020): 200–202. http://dx.doi.org/10.1097/apo.0000000000000322.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Spellman, E., and A. Page. "Chemotherapy information cards for staff administering chemotherapy." European Journal of Cancer 37 (April 2001): S412. http://dx.doi.org/10.1016/s0959-8049(01)81969-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Rosell, R., M. Taron, A. Vergnenegre, B. Massuti, E. Carcereny, T. Moran, I. Magri, S. Benlloch, J. J. Sanchez, and M. Sanchez Ronco. "38IN CHEMOTHERAPY SELECTION ACCORDING TO CHEMOTHERAPY BIOMARKERS." Lung Cancer 71 (February 2011): S22—S23. http://dx.doi.org/10.1016/s0169-5002(11)70175-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Schorge, John O. "Chemotherapy-free, but not quite free chemotherapy." Lancet Oncology 20, no. 10 (October 2019): 1335–37. http://dx.doi.org/10.1016/s1470-2045(19)30492-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ando, Yuichi, Akiko Ota, and Rie Tsuboi. "Introduction of chemotherapy (Molecular targeting agent・Chemotherapy)." Toukeibu Gan 42, no. 3 (2016): 309–15. http://dx.doi.org/10.5981/jjhnc.42.309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Faot, Nikson Eduard, and Isnu Pradjoko. "Correlation Between Neutrofil-Limphocyte Ratio Before Chemoteraphy and Objective Response Platinum based Chemoteraphy on Lung Cancer Patient." Jurnal Respirologi Indonesia 37, no. 4 (September 17, 2017): 293–98. http://dx.doi.org/10.36497/jri.v37i4.84.

Full text

Abstract:

Background: Lung cancer is the leading cause of death from cancer. One type of cancer is non-small cell lung cancer (NSCLC). The body fights against cancer cells by immune surveillance mechanisms involving the role of neutrophils and lymphocytes. Chemotherapy is a modality that is usually used as a therapy in patients’ NSCLC. To assess chemotherapy’s prognostic, research needs to be done to find the relationship between the neutrophil-lymphocytes ratio before chemotherapy with objective response after chemotherapy in patients with NSCLC Methods: This study was an observational study of retrospective cohort analytics which samples are secondary data from medical records of NSCLC patients in RSUD Dr. Soetomo who received chemotherapy by linking the neutrophils-lymphocytes ratio before chemotherapy with objective response after chemotherapy based on RECIST’s criteria and analyzed by spearman correlation test method and RNL cut off value with ROC curve and kappa test Results: Sixty-four subjects were analyzed in this study, the relationship of neutrophil-lymphocyte ratio with chemotherapy objective response after 2 cycles with P=0.354 (

APA, Harvard, Vancouver, ISO, and other styles

42

Derks, Jules L., Robert Jan van Suylen, Erik Thunnissen, Michael A. den Bakker, Harry J. Groen, Egbert F. Smit, Ronald A. Damhuis, Esther C. van den Broek, Ernst-Jan M. Speel, and Anne-Marie C. Dingemans. "Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?" European Respiratory Journal 49, no. 6 (June 2017): 1601838. http://dx.doi.org/10.1183/13993003.01838-2016.

Full text

Abstract:

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC.The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemotherapy-treated LCNEC (2003–2012). For 207 patients, histology slides were available for pathology panel review. First-line platinum-based combined chemotherapy was clustered as “NSCLC-t”, comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; “NSCLC-pt”, with pemetrexed treatment only; and “SCLC-t”, consisting of etoposide chemotherapy.A panel review diagnosis of LCNEC was established in 128 out of 207 patients. NSCLC-t chemotherapy was administered in 46% (n=60), NSCLC-pt in 16% (n=20) and SCLC-t in 38% (n=48) of the patients. The median (95% CI) overall survival for NSCLC-t chemotherapy was 8.5 (7.0–9.9) months, significantly longer than patients treated with NSCLC-pt, with a median survival of 5.9 (5.0–6.9) months (hazard ratio 2.51, 95% CI 1.39–4.52; p=0.002) and patients treated with SCLC-t chemotherapy, with a median survival of 6.7 (5.0–8.5) months (hazard ratio 1.66, 95% CI 1.08–2.56; p=0.020).In patients with LCNEC, NSCLC-t chemotherapy results in longer overall survival compared to NSCLC-pt and SCLC-t chemotherapy.

APA, Harvard, Vancouver, ISO, and other styles

43

Cai, Runkai, Jianwei Zhang, Yue Cai, Zehua Wu, Huabin Hu, Xiaoyu Xie, Yanhong Deng, Yi Cheng, and Yuting Zhang. "Adjuvant chemotherapy in ypStage III locally advanced rectal cancer after neoadjuvant treatment with an oxaliplatin-based regimen." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e15628-e15628. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15628.

Full text

Abstract:

e15628 Background: Fluorouracil -based neoadjuvant chemoradiotherapy(CRT) followed by total mesorectal excision and adjuvant chemotherapy is the standard treatment for locally advanced rectal cancer (LARC). Adjvuant FOLFOX improved survival benefit compared with fluorouracil in patients with ypStage II andIII after CRT. However, induction or consolidation chemotherapy with FOLFOX before surgery had been the new standard for LARC. Whether adjuvant chemotherapy with FOLFOX still improves survival outcomes in ypStage III patients previously exposed to oxaliplatin-based treatment was unknwon. Methods: Patients with LARC receiving oxaliplatin-based neoadjuvant treatment from January 2015 to December 2019 were retrospective analyzed. The inclusion criteria included neoadjuvant FOLFOX chemotherapy alone or induction chemotherpay, concurrent FOLFOX and consolidation chemotherapy before CRT. The duration of neoadjuvant oxaliplatin exposure time was less than 4 months. The efficacy of adjvuant FOLFOX chemotherapy was analyzed among these ypStage III patients according to adjuvant chemotherapy cycles after surgery. Results: A total of 227 patients with ypStage III were enrolled, with the 3-year DFS rate of 46.1% (95%Cl 37.3%-54.9%).Among these patients, 193 patients received adjuvant FOLFOX chemotherapy, including 7 patients had ≤ 2 cycles of adjuvant treatment. And 34 patients had observation after surgery. The 3-year DFS rates bewteen FOXFOL adjvuant chemotherapy group and observation group were 44.7% vs. 56.5%, respectively (HR, 1.190, 95%Cl 0.6246-2.267, P = 0.597). Forty-one patients had ≤ 2 cycles of adjuvant treatment. The 3-year DFS was 43.6% vs. 60.4% (P = 0.597) between pateints receiving over 2 cycles of adjvuant chemotherapy and ≤ 2 cycles of treatment. Conclusions: Among ypStage III LARC pateints after neoadjuvant treatment with Oxaliplatin-Based regimen, adjuvant chemotherapy with FOLFOX failed to improved surival benefit. More enhanced regimen might be necessary for these oxalipatin-resistant patients.

APA, Harvard, Vancouver, ISO, and other styles

44

Bhandari, Bharti, Bharati Mehta, Manisha Mavai, and Yogendra Raj Singh. "Chemotherapy Induced Peripheral Neuropathy; Mechanism and Treatment." International Physiology 4, no. 2 (2016): 73–76. http://dx.doi.org/10.21088/ip.2347.1506.4216.6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Issoual, K., A. Alaoui, K. Achehboune, S. Gallouj, S. Elloudi, H. Baybay, and F. Z. Mernissi. "Photo-Onycholysis : A Particular Chemotherapy-Induced Complication." Dermatology and Dermatitis 5, no. 1 (March 31, 2020): 01–03. http://dx.doi.org/10.31579/2578-8949/062.

Full text

Abstract:

Onycholysis or photo-onycholysis is a partial or total separation of the nail from the nail-bed secondary to chemotherapy, either alone or associated to ultraviolet phototherapy. It’is not a common side effect of anticancer therapy, even rarer with Paclitaxel. We report here one case.

APA, Harvard, Vancouver, ISO, and other styles

46

Chellappan, Sheeba. "Protocol for Preparation and Administration of Chemotherapy." Indian Journal of Holistic Nursing 09, no. 02 (September 17, 2018): 12–15. http://dx.doi.org/10.24321/2348.2133.201803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Carro, George W., Bruce Brockstein, Thomas A. Hensing, Patrick Joseph Fleming, Shannon Maureen Gavin, Wayne Spath, Abigail Harper, Wendy Hui, William J. Uhlig, and Brad Hughes. "Evaluation of oral chemotherapy prescribing at an outpatient oncology clinic." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 191. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.191.

Full text

Abstract:

191 Background: Oral chemotherapy’s exponentially increasing role in the treatment of malignancies continues to pose unique challenges to oncology. The American Society of Clinical Oncology (ASCO) and Oncology Nursing Society (ONS) drafted measures in the Chemotherapy Administration Safety Standards that help address some of these issues concerning oral chemotherapy. There is a lack of data describing the prescribing process for oral chemotherapy. In a retrospective chart review, prescriptions at a hospital-based outpatient oncology center were evaluated for completeness of prescribing and follow up measures. Methods: A retrospective chart review of ten oral chemotherapy medications from May 2012 to July 2012 was conducted. The primary outcome measure was compliance with ASCO and ONS Chemotherapy Administration Safety Standards. A secondary outcome was frequency of pharmacist interventions on oral chemotherapy prescriptions. Results: 412 prescriptions were evaluated. Prescriptions were graded on a scale from 1 to 8. One point was given for inclusion of each of the following: prescribing physician, patient name, drug name, dose, dosing methodology, quantity, refills, and accurate directions. Of all the prescriptions, 23% contained all aspects of a complete prescription. The most common reasons for point deductions were contradictory or unclear directions and allowing refills for oral chemotherapy which should not be refillable. Four percent of prescriptions had a documented pharmacist intervention. Conclusions: This study revealed areas for improvement in the prescribing process of oral chemotherapy. Targeting directions and refill fields within prescription templates will improve compliance with ASCO and ONS standards. This can be accomplished by implementing customized oral chemotherapy prescription templates within treatment plans in the electronic medical record system. Unlike chemotherapy administered in the clinic setting, oral chemotherapy prescriptions are not generally reviewed by oncology trained pharmacists. With the collaboration of medical and nursing staff, a new work flow was implemented which includes pharmacist review of electronic oral chemotherapy prescriptions.

APA, Harvard, Vancouver, ISO, and other styles

48

Cazzaniga, Marina Elena, Nicoletta Cordani, Serena Capici, Viola Cogliati, Francesca Riva, and Maria Grazia Cerrito. "Metronomic Chemotherapy." Cancers 13, no. 9 (May 6, 2021): 2236. http://dx.doi.org/10.3390/cancers13092236.

Full text

Abstract:

Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi-target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as breast and no small cell lung cancer (NSCLC), see what is new regarding most recent data in different cancer types, such as glioblastoma (GBL) and acute myeloid leukemia (AML), and new drugs with potential metronomic administration. Finally, a look at the strategic use of mCHT in the context of health emergencies, or in low –and middle-income countries (LMICs), where access to adequate healthcare is often not easy, is mandatory, as we always need to bear in in mind that equity in care must be a compulsory part of our medical work and research.

APA, Harvard, Vancouver, ISO, and other styles

49

Haywood, Philip, Johan de Raad, Kees van Gool, Marion Haas, Gisselle Gallego, Sallie-Anne Pearson, Margaret Faedo, and Robyn Ward. "Chemotherapy Administration." PharmacoEconomics 30, no. 12 (December 2012): 1173–86. http://dx.doi.org/10.2165/11597280-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Richie, Jerome P. "INTRAVESICAL CHEMOTHERAPY." Urologic Clinics of North America 19, no. 3 (August 1992): 521–27. http://dx.doi.org/10.1016/s0094-0143(21)00418-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!